Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
Muñoz J, Alcaide D, Ocaña J. Muñoz J, et al. Stat Med. 2016 May 30;35(12):1933-43. doi: 10.1002/sim.6834. Epub 2015 Dec 28. Stat Med. 2016. PMID: 26707698
The 2010 US Food and Drug Administration and European Medicines Agency regulatory approaches to establish bioequivalence in highly variable drugs are both based on linearly scaling the bioequivalence limits, both take a 'scaled ave …
The 2010 US Food and Drug Administration and European Medicines Agency regulatory approaches to establish …
Algorithms for evaluating reference scaled average bioequivalence: power, bias, and consumer risk.
Tothfalusi L, Endrenyi L. Tothfalusi L, et al. Stat Med. 2017 Nov 30;36(27):4378-4390. doi: 10.1002/sim.7440. Epub 2017 Aug 29. Stat Med. 2017. PMID: 28850696
Four algorithms were evaluated in simulated 3-period and 4-period bioequivalence studies: Hyslop's approach recommended by the US FDA, the method of average bioequivalence with expanding limits requested by the European EMA, and 2 versions of th …
Four algorithms were evaluated in simulated 3-period and 4-period bioequivalence studies: Hyslop's approach recommended by the …